REQUEST A DEMO
Total
USD $0.00
Search more companies

UAB 89Bio Lithuania (Lithuania)

Main Activities: Pharmaceutical Preparation Manufacturing | Management Consulting Services
Secondary Activities: Pharmaceutical Preparation Manufacturing
Full name: UAB 89Bio Lithuania Profile Updated: January 01, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Russian Download a sample report

UAB 89Bio Lithuania is based in Lithuania, with the head office in Vilnius. It operates in the Pharmaceutical Preparation Manufacturing sector. The company was established on February 26, 2018. 1 (2025) employees currently work for UAB 89Bio Lithuania. The company’s latest financial report indicates a net sales revenue increase of 144.82% in 2024. The net profit margin of UAB 89Bio Lithuania increased by 1.91% in 2024.

Headquarters
Jogailos g. 9
Vilnius; Vilnius county; Postal Code: LT-01116

Contact Details: Purchase the UAB 89Bio Lithuania report to view the information.

Basic Information
Total Employees:
Purchase the UAB 89Bio Lithuania report to view the information.
Registered Capital:
Purchase the UAB 89Bio Lithuania report to view the information.
Financial Auditors:
Purchase the UAB 89Bio Lithuania report to view the information.
Incorporation Date:
February 26, 2018
Key Executives
Purchase this report to view the information.
Director
Ownership Details
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after UAB 89Bio Lithuania report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency EUR. Absolute financial data is included in the purchased report.
Net sales revenue
144.82%
Total operating revenue
144.82%
Net Profit (Loss) for the Period
-2.57%
Total Equity
-86.33%
Net Profit Margin
1.91%
Return on Equity (ROE)
-547.36%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?